Windtree therapeutics, inc. expanded access policy

Expanded access is a process regulated by the U.S. Food and Drug Administration (FDA) which allows pharmaceutical companies to provide investigational products to patients with serious, life-threatening diseases or conditions and who cannot participate in a clinical study.
Windtree is not currently offering expanded access to our investigational products. However, Windtree will periodically review its expanded access policy. For additional information about this policy, please contact [email protected]. Responses will be provided within approximately five (5) business days.

Get more information on FDA Expanded Access programs here (link leaves the Windtree website)